Fries informed Maddie about a voluntary clinical trial that offered the possibility of her child, Noah, receiving an immunotherapy called blinatumomab alongside standard chemotherapy. This trial was designed to assess whether the immunotherapy, which had shown promise in earlier phase trials for patients with relapsed leukemia, could be equally effective for those newly diagnosed with B-cell ALL. Noah's participation in the trial meant he would either receive the immunotherapy in addition to chemotherapy or the latest standard of care, which is chemotherapy alone. Maddie's decision to enroll Noah in the trial was driven by the hope that the additional treatment could significantly increase his chances of a full recovery and prevent the leukemia from returning.
National Clinical Trial Offers New Hope for Pediatric Leukemia Treatment

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.
Related News
Sources
Noah's Story: How a National Clinical Trial Gave One Mom an Extra Dose of Hope
urmc.rochester.eduJan 15, 2025